GLP-1s Show Benefits Beyond Weight Loss as 40 Incretin Therapies Advance
Updated
Updated · emjreviews.com · Jul 9
GLP-1s Show Benefits Beyond Weight Loss as 40 Incretin Therapies Advance
3 articles · Updated · emjreviews.com · Jul 9
Summary
Early evidence now points to GLP-1 drugs affecting far more than obesity, with reported benefits in cardiovascular disease, kidney protection, liver fibrosis, heart failure and sleep apnoea.
A Swedish study of more than 227,000 people linked semaglutide to fewer alcohol-use-disorder hospitalisations, while another study found exenatide raised smoking abstinence by 70%.
Those findings suggest some effects may be independent of weight loss, reflecting reduced systemic inflammation and direct organ effects across metabolism, addiction and inflammatory disease.
More than 40 incretin-based therapies are in development, as researchers increasingly frame obesity biology as a broader disease map that could reshape treatment much as targeted medicine transformed oncology.
Next-gen therapies promise unprecedented weight loss. Is this the beginning of the end for many chronic diseases?
With a $190B market forecast, which industries beyond food and pharma will GLP-1s unexpectedly transform by 2035?
As new drugs quiet the brain's 'addiction noise,' what are the consequences of silencing these fundamental human drives?
GLP-1 and Incretin Therapies: Breakthroughs, Barriers, and the Future of Chronic Disease Management
Overview
GLP-1 receptor agonists (GLP-1 RAs) have transformed metabolic medicine, first proving effective for type 2 diabetes and obesity. Now, their benefits are expanding rapidly, with research showing positive effects in cardiovascular disease, chronic kidney disease, and even conditions like neurodegenerative disorders and arthritis. Recent clinical trials highlight that semaglutide, a GLP-1 RA, not only improves weight and heart failure symptoms but also reduces the risk of major cardiovascular events in people with obesity and heart disease. This incretin revolution is broadening treatment options and reshaping how chronic diseases are managed.